Leishmaniasis and tumor necrosis factor alpha antagonists in the Mediterranean basin. A switch in clinical expression.
Adolescent
Adult
Aged
Aged, 80 and over
Child
Female
Humans
Immunosuppressive Agents
/ administration & dosage
Injections, Intramuscular
Leishmaniasis
/ epidemiology
Male
Mediterranean Region
/ epidemiology
Middle Aged
Recurrence
Retrospective Studies
Systematic Reviews as Topic
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Young Adult
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
13
05
2019
accepted:
15
08
2019
revised:
12
09
2019
pubmed:
31
8
2019
medline:
8
1
2020
entrez:
31
8
2019
Statut:
epublish
Résumé
Tumor necrosis factor alpha (TNF-α) blockers are recognized as a risk factor for reactivation of granulomatous infections. Leishmaniasis has been associated with the use of these drugs, although few cases have been reported. We performed a retrospective observational study including patients with confirmed leishmaniasis acquired in the Mediterranean basin that were under TNF-α blockers therapy at the moment of the diagnosis. Patients diagnosed in our hospital from 2008 to 2018 were included. Moreover, a systematic review of the literature was performed and cases fulfilling the inclusion criteria were also included. Forty-nine patients were analyzed including nine cases from our series. Twenty-seven (55.1%) cases were male and median age was 55 years. Twenty-five (51%) patients were under infliximab treatment, 20 (40.8%) were receiving adalimumab, 2 (4.1%) etanercept, one (2%) golimumab and one (2%) a non-specified TNF-α blocker. Regarding clinical presentation, 28 (57.1%) presented as cutaneous leishmaniasis (CL), 16 (32.6%) as visceral leishmaniasis (VL) and 5 (10.2%) as mucocutaneous leishmaniasis (MCL). All VL and MCL patients were treated with systemic therapies. Among CL patients, 13 (46.4%) were treated with a systemic drug (11 received L-AmB, one intramuscular antimonials and one miltefosine) while 14 (50%) patients were given local treatment (13 received intralesional pentavalent antimonials, and one excisional surgery). TNF-α blockers were interrupted in 32 patients (65.3%). After treatment 5 patients (10.2%) relapsed. Four patients with a CL (3 initially treated with local therapy maintaining TNF-α blockers and one treated with miltefosine) and one patient with VL treated with L-AmB maintaining TNF-α blockers. This data supports the assumption that the blockage of TNF-α modifies clinical expression of leishmaniasis in endemic population modulating the expression of the disease leading to atypical presentations. According to the cases reported, the best treatment strategy would be a systemic drug and the discontinuation of the TNF-α blockers therapy until clinical resolution.
Sections du résumé
BACKGROUND
Tumor necrosis factor alpha (TNF-α) blockers are recognized as a risk factor for reactivation of granulomatous infections. Leishmaniasis has been associated with the use of these drugs, although few cases have been reported.
METHODOLOGY
We performed a retrospective observational study including patients with confirmed leishmaniasis acquired in the Mediterranean basin that were under TNF-α blockers therapy at the moment of the diagnosis. Patients diagnosed in our hospital from 2008 to 2018 were included. Moreover, a systematic review of the literature was performed and cases fulfilling the inclusion criteria were also included.
PRINCIPAL FINDINGS
Forty-nine patients were analyzed including nine cases from our series. Twenty-seven (55.1%) cases were male and median age was 55 years. Twenty-five (51%) patients were under infliximab treatment, 20 (40.8%) were receiving adalimumab, 2 (4.1%) etanercept, one (2%) golimumab and one (2%) a non-specified TNF-α blocker. Regarding clinical presentation, 28 (57.1%) presented as cutaneous leishmaniasis (CL), 16 (32.6%) as visceral leishmaniasis (VL) and 5 (10.2%) as mucocutaneous leishmaniasis (MCL). All VL and MCL patients were treated with systemic therapies. Among CL patients, 13 (46.4%) were treated with a systemic drug (11 received L-AmB, one intramuscular antimonials and one miltefosine) while 14 (50%) patients were given local treatment (13 received intralesional pentavalent antimonials, and one excisional surgery). TNF-α blockers were interrupted in 32 patients (65.3%). After treatment 5 patients (10.2%) relapsed. Four patients with a CL (3 initially treated with local therapy maintaining TNF-α blockers and one treated with miltefosine) and one patient with VL treated with L-AmB maintaining TNF-α blockers.
CONCLUSIONS
This data supports the assumption that the blockage of TNF-α modifies clinical expression of leishmaniasis in endemic population modulating the expression of the disease leading to atypical presentations. According to the cases reported, the best treatment strategy would be a systemic drug and the discontinuation of the TNF-α blockers therapy until clinical resolution.
Identifiants
pubmed: 31469834
doi: 10.1371/journal.pntd.0007708
pii: PNTD-D-19-00708
pmc: PMC6742442
doi:
Substances chimiques
Immunosuppressive Agents
0
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0007708Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Arch Med Sci. 2014 Dec 22;10(6):1175-85
pubmed: 25624856
Eur J Clin Microbiol Infect Dis. 2009 Apr;28(4):331-7
pubmed: 18797940
Rheumatology (Oxford). 2012 Aug;51(8):1517-8
pubmed: 22427411
Dermatol Online J. 2012 Sep 15;18(9):7
pubmed: 23031374
Enferm Infecc Microbiol Clin. 2010 Apr;28(4):261-2
pubmed: 19729230
Front Immunol. 2017 Oct 30;8:1437
pubmed: 29163510
Clin Rheumatol. 2007 Aug;26(8):1344-5
pubmed: 16865310
BMC Infect Dis. 2010 Jul 15;10:209
pubmed: 20633260
Arch Pediatr. 2009 Oct;16 Suppl 2:S129-31
pubmed: 19836676
Dermatology. 2010;220(1):63-5
pubmed: 19907139
Microbes Infect. 2004 Oct;6(12):1102-9
pubmed: 15380780
PLoS Negl Trop Dis. 2014 Aug 21;8(8):e3021
pubmed: 25144380
Int J Mol Sci. 2018 May 11;19(5):
pubmed: 29751683
BMJ Case Rep. 2010 Oct 13;2010:
pubmed: 22789834
Clin Exp Rheumatol. 2010 Jul-Aug;28(4):590-1
pubmed: 20659417
Br J Dermatol. 2019 Aug;181(2):403-405
pubmed: 30659588
Clin Microbiol Infect. 2012 Jul;18(7):670-6
pubmed: 21985586
Immunol Rev. 2004 Oct;201:225-38
pubmed: 15361244
Enferm Infecc Microbiol Clin. 2012 Jan;30(1):40-2
pubmed: 21903302
BMJ Case Rep. 2014 Jun 10;2014:
pubmed: 24916985
Rheumatology (Oxford). 2006 Nov;45(11):1446-8
pubmed: 16887847
Ann Dermatol Venereol. 2009 Nov;136(11):815-6
pubmed: 19917436
Am J Trop Med Hyg. 2006 Nov;75(5):858-63
pubmed: 17123977
Transfusion. 2008 Jul;48(7):1383-9
pubmed: 18422844
Acta Trop. 2011 Aug;119(2-3):69-75
pubmed: 21679680
Scand J Infect Dis. 2013 Jul;45(7):567-9
pubmed: 23270475
Emerg Infect Dis. 2009 Jun;15(6):956-9
pubmed: 19523302
Transfus Apher Sci. 2017 Aug;56(4):544-551
pubmed: 28754214
Am J Trop Med Hyg. 2013 Jul;89(1):105-10
pubmed: 23629932
Am J Trop Med Hyg. 2018 May;98(5):1313-1316
pubmed: 29582737
Actas Dermosifiliogr. 2014 Sep;105(7):714-6
pubmed: 24275564
Enferm Infecc Microbiol Clin. 2004 May;22(5):310
pubmed: 15207130
Pathog Glob Health. 2016 Sep;110(6):247-260
pubmed: 27660895
Euro Surveill. 2013 Jul 25;18(30):20542
pubmed: 23929182
Med Clin (Barc). 2011 Nov 12;137(12):533-40
pubmed: 21514606
Rheumatol Int. 2013 Oct;33(10):2687-9
pubmed: 22886470
PLoS One. 2012;7(5):e35671
pubmed: 22693548
Clin Infect Dis. 2005 Aug 1;41 Suppl 3:S194-8
pubmed: 15983899
Am J Trop Med Hyg. 2009 Jul;81(1):52-4
pubmed: 19556566
Clin Rheumatol. 2008 Apr;27(4):541-2
pubmed: 17963018
J Antimicrob Chemother. 2016 Jul;71(7):1914-21
pubmed: 27084919
J Immunol. 2006 Jun 1;176(11):6656-64
pubmed: 16709824
Trends Parasitol. 2004 Nov;20(11):524-30
pubmed: 15471704
Front Immunol. 2018 Jul 31;9:1772
pubmed: 30108591
Clin Exp Rheumatol. 2009 May-Jun;27(3):503-6
pubmed: 19604446
Open Forum Infect Dis. 2016 Feb 01;3(1):ofw008
pubmed: 27042675
Med J Aust. 2013 Apr 1;198(6):331-3
pubmed: 23545033
Immunol Cell Biol. 2007 Feb-Mar;85(2):138-47
pubmed: 17146466
Acta Derm Venereol. 2009;89(4):432-3
pubmed: 19688168
Nat Rev Microbiol. 2011 Jul 11;9(8):604-15
pubmed: 21747391
Travel Med Infect Dis. 2013 Nov-Dec;11(6):412-20
pubmed: 23972958
J Exp Med. 2000 Jun 19;191(12):2121-30
pubmed: 10859337
J Clin Rheumatol. 2010 Jan;16(1):38-9
pubmed: 20051756
Am J Trop Med Hyg. 2017 Jan 11;96(1):24-45
pubmed: 27927991
Clin Exp Rheumatol. 2005 Nov-Dec;23(6):891-2
pubmed: 16396712
Front Immunol. 2016 May 13;7:187
pubmed: 27242794
Dermatol Ther. 2014 May-Jun;27(3):131-4
pubmed: 24903470
J Chemother. 2017 Oct;29(5):261-266
pubmed: 28490252
Lancet. 2018 Sep 15;392(10151):951-970
pubmed: 30126638
Expert Opin Pharmacother. 2015 Feb;16(2):237-52
pubmed: 25346016
Acta Parasitol. 2016 Jan;61(1):93-7
pubmed: 26751877
Clin Exp Dermatol. 2017 Apr;42(3):331-334
pubmed: 28239885
Joint Bone Spine. 2010 May;77(3):271-3
pubmed: 20378385
Semin Arthritis Rheum. 2013 Oct;43(2):152-7
pubmed: 23777708
PLoS Negl Trop Dis. 2017 Aug 10;11(8):e0005660
pubmed: 28796786
Dermatology. 2015;230(3):204-7
pubmed: 25633623